Amylin’s emerging role in treating combined diabetes and obesity over the past 5 years

Amylin analogs have produced weight loss exceeding 15% in combination therapies for diabetes and obesity.

• Amylin regulates blood glucose levels and appetite by delaying gastric emptying and suppressing glucagon secretion.
• Preclinical studies have led to the development of long-acting amylin analogs that improve weight loss and metabolic health in animal models.
• The synthetic analog pramlintide has been shown to modestly improve glycemic control and induce weight loss in diabetes patients.
• Cagrilintide, a long-acting amylin analog, has resulted in substantial weight reduction in individuals with obesity.
• Combining amylin analogs with glucagon-like peptide-1 receptor agonists may enhance weight loss and metabolic outcomes.

Simplified